GlassScriptPhysician profile
Haluk K Aydin
NPI 1700857836
$2,236.73
in general payments reported to CMS, 2019-2025
14 companies · $514 in 2025
The $514 reported for 2025 was more than what 76% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $576 · 2021: $111 · 2022: $23.87 · 2023: $67.08 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $602.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $378.12 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $266.75 | 2019-2025 | Uzedy |
| Alkermes, INC. | $171.47 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $166.52 | 2019-2025 | Spravato |
| Lundbeck LLC | $165.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $143.31 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $140.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.30 | 2019-2023 | Trintellix |
| Shire North American Group INC | $26.11 | 2019 | |
| Almatica Pharma LLC | $22.55 | 2023 | Gralise |
| Tris Pharma INC | $18.54 | 2019 | |
| Allergan, INC. | $12.27 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haluk Aydin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.